哌拉西林联合阿奇霉素治疗肺炎支原体性肺炎的临床疗效及安全性  

Clinical Efficacy and Safety of Piperacillin Combined with Azithromycin in the Treatment of Mycoplasma Pneumoniae Pneumonia

作　　者：郭能 陈英 GUO Neng;CHEN Ying(Department of Pediatrics,Xiajiang County People's Hospital,Xiajiang 331409,Jiangxi,China)

机构地区：[1]峡江县人民医院儿科,江西峡江331409

出　　处：《医学信息》2025年第7期109-112,共4页Journal of Medical Information

摘　　要：目的探讨哌拉西林联合阿奇霉素治疗肺炎支原体性肺炎的临床疗效及安全性。方法按照随机数字表法将2021年1月-2023年10月峡江县人民医院接诊的支原体性肺炎患儿60例分为对照组和研究组,每组30例。对照组应用阿奇霉素干混悬剂治疗,研究组在对照组基础上采用哌拉西林钠他唑巴坦钠治疗。比较两组临床疗效、临床症状(发热、气促、咳嗽、肺部啰音)评分、血清炎性因子水平[C反应蛋白(CRP)、降钙素原(PCT)、白细胞介素-6(IL-6)、白细胞介素-1(IL-1)]、不良反应(恶心、发烧、呕吐、腹痛)发生率。结果研究组治疗总有效率为96.67%,对照组治疗总有效率为73.33%,组间比较,差异有统计学意义(P<0.05);与对照组比较,研究组治疗后临床症状评分、血清炎性因子水平(CRP、PCT、IL-6、IL-1)降低,差异有统计学意义(P<0.05);研究组不良反应发生率为23.33%,对照组不良反应发生率为20.00%,组间比较,差异无统计学意义(P>0.05)。结论哌拉西林联合阿奇霉素治疗肺炎支原体性肺炎的临床疗效确切,可以促进患者临床症状改善,缓解机体炎症反应,降低不良反应发生风险,具有较高的安全性。Objective To investigate the clinical efficacy and safety of piperacillin combined with azithromycin in the treatment of mycoplasma pneumoniae pneumonia.Methods According to the random number table method,60 children with mycoplasma pneumonia admitted to Xiajiang County People's Hospital from January 2021 to October 2023 were divided into control group and study group,with 30 children in each group.The control group was treated with azithromycin dry suspension,and the study group was treated with piperacillin sodium and tazobactam sodium on the basis of the control group.The clinical efficacy,clinical symptoms(fever,shortness of breath,cough,pulmonary rales)scores,serum inflammatory factor levels[C-reactive protein(CRP),procalcitonin(PCT),interleukin-6(IL-6),interleukin-1(IL-1)],and incidence of adverse reactions(nausea,fever,vomiting,abdominal pain)were compared between the two groups.Results The total effective rate of the study group was 96.67%,and the total effective rate of the control group was 73.33%,the difference between the two groups was statistically significant(P<0.05).Compared with the control group,the clinical symptom score and serum inflammatory factor levels(CRP,PCT,IL-6,IL-1)in the study group decreased after treatment,and the difference were statistically significant(P<0.05).The incidence of adverse reactions in the study group was 23.33%,and the incidence of adverse reactions in the control group was 20.00%,but there was no significant difference between the two groups(P>0.05).Conclusion Piperacillin combined with azithromycin has a definite clinical effect in the treatment of mycoplasma pneumoniae pneumonia,which can promote the improvement of clinical symptoms,relieve the body's inflammatory response,reduce the risk of adverse reactions,and has high safety.

关 键 词：哌拉西林 阿奇霉素 支原体性肺炎 炎性因子水平 

分 类 号：R725.6[医药卫生—儿科]